Finance

Lists
ABTT34:BVMF
Abbott Laboratories BDR
42,45 R$
0,00%
(0,00) 1D
2 ოქტ, 16:56:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for ABTT34...
Open
42,18 R$
High
42,45 R$
Low
42,18 R$
Mkt. cap
168,71 მლრ.
Avg. vol.
263,00
Volume
57,00
52-wk high
60,34 R$
52-wk low
33,34 R$
Shares outstanding
1,73 მლრდ.
No. of employees
115 ათ.
Open
42,18 R$
High
42,45 R$
Low
42,18 R$
Mkt. cap
168,71 მლრ.
Avg. vol.
263,00
Volume
57,00
52-wk high
60,34 R$
52-wk low
33,34 R$
Shares outstanding
1,73 მლრდ.
No. of employees
115 ათ.
News stories
From web sources and news partners
Profile
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company founded in Chicago with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices. Abbott operates in over 160 countries and sources from at least 62 suppliers worldwide. Abbott's products include Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip. The company is ranked 107th on the Fortune 500 and 144th on the Forbes Global 2000. Wikipedia
About Abbott Laboratories BDR
CEOრობერ ბი ფორდ
Employees115 ათ.
Founded1888
Headquartersჩიკაგო, ილინოისი, ამერიკის შეერთებული შტატები
SectorMedical device
Websiteabbott.com
Last report
16 ივლ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
1,31 US$ / 1,28 US$
+2,61%beat
Revenue / Est. (USD)
12,59 მლრდ. / 12,52 მლრდ.
+0,61%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
11,37 მლრდ.
11,46 მლრდ.
11,16 მლრდ.
12,59 მლრდ.
Cost of goods sold
5,08 მლრდ.
4,91 მლრდ.
4,89 მლრდ.
5,32 მლრდ.
Cost of revenue
5,08 მლრდ.
4,91 მლრდ.
4,89 მლრდ.
5,32 მლრდ.
Research and development expenses
766,00 მლნ.
720,00 მლნ.
767,00 მლნ.
892,00 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,90 მლრდ.
2,93 მლრდ.
3,58 მლრდ.
3,87 მლრდ.
Operating expense
4,09 მლრდ.
4,07 მლრდ.
4,77 მლრდ.
5,42 მლრდ.
Total operating expenses
9,16 მლრდ.
8,98 მლრდ.
9,66 მლრდ.
10,74 მლრდ.
Operating income
2,20 მლრდ.
2,48 მლრდ.
1,50 მლრდ.
1,85 მლრდ.
Other non operating income
2,00 მლნ.
-15,00 მლნ.
-
-25,00 მლნ.
EBT including unusual items
2,18 მლრდ.
2,36 მლრდ.
1,45 მლრდ.
1,52 მლრდ.
EBT excluding unusual items
2,18 მლრდ.
2,44 მლრდ.
1,45 მლრდ.
1,52 მლრდ.
Income tax expense
536,00 მლნ.
582,00 მლნ.
372,00 მლნ.
596,00 მლნ.
Effective tax rate
24,59%
24,68%
25,67%
39,11%
Other operating expenses
-
-
-
-
Net income
1,64 მლრდ.
1,78 მლრდ.
1,08 მლრდ.
928,00 მლნ.
Net profit margin
14,46%
15,50%
9,65%
7,37%
Earnings per share
1,30
1,50
1,15
1,31
Interest and investment income
77,00 მლნ.
78,00 მლნ.
106,00 მლნ.
52,00 მლნ.
Interest expense
-121,00 მლნ.
-120,00 მლნ.
-174,00 მლნ.
-351,00 მლნ.
Net interest expenses
-44,00 მლნ.
-42,00 მლნ.
-68,00 მლნ.
-299,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
3,00 მლრდ.
3,27 მლრდ.
2,31 მლრდ.
2,91 მლრდ.
Gain or loss from assets sale
-
65,00 მლნ.
-
-
AI content may include mistakes. Learn more
Google აპები